TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes

Journal of Immunology

Volumn 183, Issue 2, 2009, Pages 1144-1154

  Thaxton, Jessica E ^a   Romero, Roberto ^b   Sharma, Surendra ^a  

^a BROWN UNIVERSITY   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 10; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA; TLR9 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; CRANIOFACIAL MALFORMATION; CYTOKINE PRODUCTION; FEMALE; GESTATIONAL AGE; INNATE IMMUNITY; LIMB DEFECT; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PLACENTA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; PUP (RODENT); UTERUS; WILD TYPE; ANIMAL; BIOSYNTHESIS; BONE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CONGENITAL MALFORMATION; FETUS RESORPTION; IMMUNOLOGY; METABOLISM; MOUSE MUTANT; PATHOLOGY;

ANIMALS; BONE AND BONES; FEMALE; FETAL RESORPTION; INTERLEUKIN-10; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEUTROPHILS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA; UTERUS;

EID: 70249085959     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900788     Document Type: Article

References (60)

1. Goldenberg, R. L., J. C. Hauth, and W. W. Andrew. 2000. Intrauterine infection and preterm delivery. N. Engl. J. Med. 342: 1500-1507.
2. Romero, R., J. Espinoza, and M. Mazor. 2004. Can endometrial infection/inflammation explain implantation failure, spontaneous abortion, and preterm birth after in vitro fertilization? Fertil. Steril. 82: 799-804.
3. Moffett-King, A. 2002. Natural killer cells and pregnancy. Nat. Rev. Immunol. 2: 656-663.
4. Whitelaw, P. F., and B. A. Croy. 1996. Granulated lymphocytes of pregnancy. Placenta 17: 533-543.
5. Ain, R., L. N. Canham, and M. J. Soares. 2003. Gestational stage-dependent intrauterine trophoblast cell invasion in the rat and mouse: novel endocrine phenotype regulation. Dev. Biol. 260: 176-190.
6. Hanna, J., D. Goldman-Wohl, Y. Hamani, I. Avraham, C. Greenfield, S. Natanson-Yaron, D. Prus, L. Cohen-Daniel, T. I. Arnon, I. Manaster, et al. 2006. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12: 1065-1074.
7. Kalkunte, S., C. O. Chichester, F. Gotsch, C. L. Sentman, R. Romero, and S. Sharma. 2008. Evolution of non-cytotoxic uterine natural killer cells. Am. J. Reprod. Immunol. 59: 425-432.
8. Kalkunte, S., T. F. Mselle, W. E. Norris, C. R. Wira, C. L. Sentman, and S. Sharma. 2009. VEGF C facilitates immune tolerance and endovascular activity of human uterine NK cells at the maternal-fetal interface. J. Immunol. 182: 4085-4092.
9. Murphy, S. P., L. D. Fast, N. N. Hanna, and S. Sharma. 2005. Uterine NK cells mediate inflammation-induced fetal demise in IL-10-null mice. J. Immunol. 175: 4084-4090.
10. Murphy, S. P., N. N. Hanna, L. D. Fast, S. K. Shaw, G. Berg, J. F. Padbury, R. Romero, and S. Sharma. 2009. Evidence for participation of uterine NK cells in the mechanisms responsible for spontaneous preterm labor and delivery. Am. J. Obstet. Gynecol. 200: 308e1-308e9.
11. Sentman, C. L., C. R. Wira, and M. Eriksson. 2007. NK cell function in the human female reproductive tract. Am. J. Reprod. Immunol. 57: 108-115.
12. Patni, S., L. P. Wynen, A. L. Seager, G. Morgan, J. O. White, and C. A. Thornton. 2009. Expression and Activity of Toll-like receptors 1-9 in the human term placenta and changes associated with labor at term. Biol. Reprod. 80: 243-248.
13. Krikun, G., C. J. Lockwood, V. M. Abrahams, G. Mor, M. Paidas, and S. Guller. 2007. Expression of Toll-like receptors in the human decidua. Histol. Histopathol. 22: 847-854.
14. Barton, G. M., and R. Medzhitov. 2002. Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. 270: 81-92.
15. Uematsu, S., and S. Akira. 2006. Toll-like receptors and innate immunity. J. Mol. Med. 84: 712-725.
16. Trinchieri, G., and A. Sher. 2007. Cooperation of Toll-like receptor signals in innate immune defence. Nat. Rev. Immunol. 7: 179-190. (Pubitemid 46310482)
17. Krieg, A. M. 2002. CpG Motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
18. Pedersen, G., L. Andresen, M. W. Matthiessen, J. Rask-Madsen, and J. Brynskov. 2005. Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin. Exp. Immunol. 141: 298-306.
19. Prater, M. R., V. J. Johnson, D. R. Germolec, M. I. Luster, and S. D. Holladay. 2006. Maternal treatment with a high dose of CpG ODN during gestation alters fetal craniofacial and distal limb development in C57BL/6 mice. Vaccine 24: 263-271.
20. Ito, S., K. J. Ishii, H. Shirota, and D. M. Klinman. 2004. CpG oligodeoxynucleotides improve survival of pregnant and fetal mice following Listeria monocytogenes infection. Infect. Immun. 72: 354-358.
21. Carpentier, A. F., L. Chen, F. Maltonti, and J. Y. Delattre. 1999. Oligodeoxynucleotides containing CpG motifs can induce rejection of neuroblastoma in mice. Cancer Res. 59: 5429-5432.
22. Carpentier, A. F., J. Xie, K. Mokhtari, and J. Y. Delattre. 2000. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin. Cancer Res. 6: 2469-2473.
23. Meng, Y., A. F. Carpentier, L. Chen, G. Boisserie, J. M. Simon, J. J. Mazeron, and J. Y. Delattre. 2005. Successful combination of local CpG-ODN and radiotherapy in malignant glioma. Int. J. Cancer 116: 992-997.
24. Becker, Y. 2005. CpG ODNs treatments of HIV-1 infected patients may cause the decline of transmission in high risk populations: a review, hypothesis and implications. Virus Genes 30: 251-266.
25. Kline, J. N., and A. M. Krieg. 2008. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 21: 434-439.
26. Manegold, C., D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsch, M. Al-Adhami, D. Readett, A. M. Krieg, and C. G. Leichman. 2008. Randomized phase II trial of Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced stage nonsmall-cell lung cancer. J. Clin. Oncol. 26: 3979-3986.
27. Chaung, H. C. 2006. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy. Int. Immunopharmacol. 6: 1586-1596.
28. Jenkins, M., C. Parker, W. Tuo, B. Vinyard, and J. P. Dubey. 2004. Inclusion of CpG adjuvant with plasmid DNA coding for NcGRA7 improves protection against congenital neosporosis. Infect. Immun. 72: 1817-1819.
29. Roche, J. K., T. R. Keepers, L. K. Gross, R. M. Seaner, and T. G. Obrig. 2007. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli 0157:H7-associated renal inflammation. Am. J. Pathol. 170: 526-537.
30. Siewe, L., M. Bollati-Fogolin, C. Wickenhauser, T. Krieg, W. Muller, and A. Rogers. 2006. Interleukin-10 derived from macrophages and/or neutrophils regulates the inflammatory response to LPS but not the response to CpG DNA. Eur. J. Immunol. 36: 3248-3255.
31. Redecha, P., R. Tilley, M. Tencati, J. E. Salmon, D. Kirchhofer, N. Mackman, and G. Girardi. 2007. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. Blood 110: 2423-2431.
32. Ballas, Z. K., A. M. Krieg, T. Warren, W. Rasmussen, H. L. Davis, M. Waldschmidt, and G. J. Weiner. 2001. Divergent therapeutic and immunologic effect of oligodeoxynucleotides with distinct CpG motifs. J. Immunol. 167: 4878-4886.
33. Beloeil, L., M. Tomkowiak, G. Angelov, T. Walzer, P. Dubois, and J. Marvel. 2003. In vivo impact of CpG1826 oligodeoxynucleotide on CD8 T cell primary responses and survival. J. Immunol. 171: 2295-3002.
34. Dragoi, A. M., X. Fu, S. Ivanov, P. Zhang, L. Sheng, D. Wu, G. C. Li, and W. M. Chu. 2005. DNA-PKCs, but not TLR9, is required for activation of Akt by CpG-DNA. EMBO J. 24: 779-789.
35. Verthelyi, D., and A. R. Zeuner. 2003. Differential signaling by CpG DNA in DCs and B cells: not just TLR9. Trends Immunol. 24: 519-522.
36. Krieg, A. M., T. Wu, R. Weeratna, S. M. Efler, L. Love-Homan, L. Yang, A. K. Yi, D. Short, and H. L. Davis. 1998. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA 95: 12631-12636.
37. Gursel, I., M. Gursel, H. Yamada, K. J. Ishii, F. Takeshita, and D. M. Klinman. 2003. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J. Immunol. 171: 1393-1400.
38. Stunz, L. L., P. Lenert, D. Peckham, A. K. Yi, S. Haxhinasto, M. Chang, A. M. Krieg, and R. F. Ashman. 2002. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur. J. Immunol. 32: 1212-1222.
39. Piccini, M. P. 2005. T cells in pregnancy. Chem. Immunol. Allergy 89: 3-9.
40. Renaud, S. J., and C. H. Graham. 2008. The role of macrophages in utero-placental interactions during normal and pathological pregnancy. Immunol. Invest. 37: 535-564.
41. Rothenfusser, S., E. Tuma, S. Endres, and G. Hartmann. 2002. Plasmacytoid dendritic cells: the key to CpG. Hum. Immunol. 63: 1111-1119.
42. Nardini, E., D. Morelli, P. Aiello, D. Besusso, C. Calcaterra, L. Mariani, M. Palazzo, A. Vecchi, S. Paltrinieri, S. Menard, and A. Balsari. 2005. CpG-oligodeoxynucleotides induce mobilization of hematopoetic progenitor cells into peripheral blood in association with mouse KC (IL-8) production. J. Cell Physiol. 204: 889-895.
43. Wood, G. W., E. Hausmann, and R. Choudhuri. 1997. Relative role of CSF-1, MCP-1/JE, and RANTES in macrophage recruitment during successful pregnancy. Mol. Reprod. Dev. 46: 62-69.
44. Daley, J. M., A. A. Thomay, M. D. Connolly, J. S. Reichner, and J. E. Albina. 2008. Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J. Leukocyte Biol. 83: 64-70.
45. Klinman, D. M. 2006. Adjuvant activity of CpG oligodeoxynucleotides. Int. Rev. Immunol. 25: 135-154.
46. Lee, J. G., S. H. Lee, D. W. Park, S. H. Lee, H. S. Yoon, B. R. Chin, J. H. Kim, J. R. Kim, and S. H. Baek. 2008. Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling. Cell Signal. 20: 105-115.
47. József, L., T. Khreiss, D. El Kebir, and J. G. Filep. 2006. Activation of TLR-9 induces IL-8 secretion through peroxynitrite signaling in human neutrophils. J. Immunol. 176: 1195-1202. (Pubitemid 43099723)
48. Mor, G., R. Romero, P. B. Aldo, and V. M. Abrahams. 2005. Is the trophoblast an immune regulator? The role of Toll-like receptors during pregnancy. Crit. Rev. Immunol. 25: 375-388.
49. Mosca, F., and L. Pugni. 2007. Cytomegalovirus infection: the state of the art. J. Chemother. 2: 46-48.
50. Pararas, M. V., C. L. Skevaki, and D. A. Kafetzis. 2006. Preterm birth due to maternal infection: Causative pathogens and modes of prevention. Eur. J. Clin. Microbiol. Infect. Dis. 25: 562-569.
51. Hanna, N., L. Bonifacio, B. Weinberger, P. Reddy, S. Murphy, R. Romero, and S. Sharma. 2006. Evidence for interleukin-10-mediated inhibition of cyclo-oxygenase-2 expression and prostaglandin production in preterm human placenta. Am. J. Reprod. Immunol. 55: 19-27.
52. Annells, M. F., P. H. Hart, C. G. Mullighan, S. L. Heatley, J. S. Robinson, P. Bardy, and H. M. McDonald. 2004. Interleukins-1, -4, -6, -10, tumor necrosis factor, transforming growth factor-β, FAS, and mannose-binding protein C gene polymorphisms in Australian women: risk of preterm birth. Am. J. Obstet. Gynecol. 191: 2056-2067.
53. Kerk, J., D. B. Bartels, M. J. Brinkhaus, C. E. Dammann, T. Dörk, and O. Mammann. 2006. Multiplex measurement of cytokine/receptor gene polymorphisms and interaction between interleukin-10 (-1082) genotype and chorioamnionitis in extreme preterm delivery. J. Soc. Gynecol. Investig. 13: 350-356.
54. Menon, R., M. Merialdi, S. J. Lombardi, and S. J. Fortunato. 2006. Differences in the placental membrane cytokine response: a possible explanation for the racial disparity in preterm birth. Am. J. Reprod. Immunol. 56: 112-118.
55. Kim, Y. M., M. M. Brinkmann, M. E. Paquet, and H. L. Ploegh. 2008. UNC93B1 delivers nucleotide-sensing Toll-like receptors to endolysosomes. Nature 452: 234-238.
56. Latz, E., A. Schoenemeyer, A. Visintin, K. A. Fitzgerald, B. G. Monks, C. F. Knetter, E. Lien, N. J. Nilsen, T. Espevik, and D. T. Golenbock. 2004. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5: 190-198.
57. Bhan, U., N. W. Lukacs, J. J. Osterholzer, M. W. Newstead, X. Zeng, T. A. Moore, T. R. McMillan, A. M. Krieg, S. Akira, and T. J. Standiford. 2007. TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J. Immunol. 179: 3937-3946.
58. Liese, J., U. Schleicher, and C. Bogdan. 2007. TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur. J. Immunol. 37: 3424-3434.
59. Buhtoiarov, I. N., P. M. Sondel, J. C. Eickhoff, and A. L. Rakhmilevich. 2007. Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides. Immunology 120: 412-423.
60. Alvarez, M. E., J. I. Fuxman Bass, J. R. Geffner, P. X. Calotti, M. Costas, O. A. Coso, R. Gamberale, M. E. Vermeulen, G. Salamone, D. Martinez, et al. 2006. Neutrophil signaling pathways activated by bacterial DNA stimulation. J. Immunol. 177: 4037-4046.